

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	
Brand Name	Dexcom G7® continuous glucose monitoring (CGM) system
Manufacturer	Dexcom Canada Co.
Submission Type	New Submission
Use Reviewed	For glucose monitoring in patients with diabetes mellitus
Canadian Agency for Drugs and Technologies in Health (CADTH) Reimbursement Reviews (CRR)	No, the CRR did not review
Provincial Review	The CGMs and flash glucose monitors (FGMs) were reviewed internally and various inputs were considered, including: the recommendations of BC's Health Technology Assessment Committee (HTAC); the findings of the Health Technology Assessment systematic review and network meta-analyses; implementation advice from the Canadian Agency for Drugs and Technologies in Health (CADTH); Patient Input Questionnaire responses from 1,837 patients, 541 caregivers and 12 patient groups; budget impact assessments; and stakeholder feedback from endocrinologists, diabetes education centers, Nursing Support Services from BC Children's Hospital, and patient advocacy groups.
Drug Coverage Decision	Limited Coverage Benefit. Access the Dexcom G7 CGM criteria from www.gov.bc.ca/pharmacarespecialauthority
Date	November 7, 2023

<p>Reasons</p>	<p>Drug coverage decision is consistent with the HTAC recommendation.</p> <ul style="list-style-type: none"> • The Dexcom G7 CGM is an update to the current Dexcom G6 CGM, which is a PharmaCare Limited Coverage benefit. • At the submitted list price, the Dexcom G7 CGM sensor is less costly than the list price of the Dexcom G6 sensor. Additionally, the Dexcom G7 CGM does not require the purchase of a transmitter to transmit blood glucose readings to the receiver device. • BC’s HTAC concluded that glucose monitoring technologies, including CGMs, FGMs, and hybrid closed loop insulin delivery systems, provide no additional clinical benefits compared to fingerprick blood glucose tests, but provide non-clinical benefits. • The HTAC recommended that funding be provided based on functional, not clinical, need and that the Ministry of Health (the Ministry) should consult stakeholders to define eligible populations. • Stakeholder input and patient input suggested that FGMs and CGMs were a major advancement in technology compared to fingerprick blood glucose tests, and, when used correctly, they have the potential to improve the health of patients with diabetes.
<p>Other Information</p>	<p>Information regarding the HTAC’s recommendations and the Health Technology Assessment systematic review and network meta-analyses are available online.</p>

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Canadian Agency for Drugs and Technologies in Health \(CADTH\) Reimbursement Reviews\(CRR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.

